Payload Information
General Information of This Payload
| Payload ID | PAY0POFAD |
|||||
|---|---|---|---|---|---|---|
| Name | DHT |
|||||
| Synonyms |
DHT
Click to Show/Hide
|
|||||
| Structure |
|
|||||
| Formula | C19H30O2 |
|||||
| Isosmiles | C[C@]1(CC2)[C@@]([C@]([C@@]2([H])[C@]3(CC4)C)([H])CC[C@@]3([H])CC4=O)([H])CC[C@@H]1O |
|||||
| PubChem CID | ||||||
| InChI |
InChI=1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12,14-17,21H,3-11H2,1-2H3/t12-,14-,15-,16-,17-,18-,19-/m0/s1
|
|||||
| InChIKey |
NVKAWKQGWWIWPM-ABEVXSGRSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
290.447 |
Polar area |
37.3 |
||
Complexity |
617.52785 |
xlogp Value |
3.9591 |
|||
Heavy Count |
21 |
Rot Bonds |
0 |
|||
Hbond acc |
2 |
Hbond Donor |
1 |
|||
The activity data of This Payload
| Standard Type | Value | Units | Cell line | Disease Model | Cell line ID | Reference |
|---|---|---|---|---|---|---|
| Cell-based Percent Inhibition (%) | -0.07 | % |
Vero C1008 cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | -0.07 | % |
Vero C1008 cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | -0.07795 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | -2.65 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 0 | pm/min/mg | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 0 | pm/min/mg | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 0 | pm/min/mg | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 0.18 | g | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 0.2 | g | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 100 | % |
PC-3 cells
|
Prostate carcinoma
|
||
| Cellular activity | 100 | % |
LNCaP cells
|
Prostate carcinoma
|
||
| Cellular activity | 100 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 100 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 138 | kN/m2 | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 14 | pm/min/mg | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 14 | pm/min/mg | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 18 | pm/min/mg | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 18 | total picomoles | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 180 | % |
HEK293 cells
|
Normal
|
||
| Cellular activity | 182 | pm/min/mg | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 190 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 2 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 2 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 2.7 | uM (g of spores)-1 | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 2.9 | uM (g of spores)-1 | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 200 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 203 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 208 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 209 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 28.8 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 3 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 320 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 36 | pm/min/mg | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 39.4 | pm/min/mg | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 4.2 | uM (g of spores)-1 | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 43 | pm/min/mg | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 49.6 | % |
HEK293 cells
|
Normal
|
||
| Cellular activity | 5.8 | uM (g of spores)-1 | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 50 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 50.5 | mg | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 51.5 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 56.7 | mg | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 6.68 | % |
Caco-2 cells
|
Colon adenocarcinoma
|
||
| Cell-based Percent Inhibition (%) | 6.85 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 60.4 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 62 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 70 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 73 | % |
CV-1 cells
|
Normal
|
||
| Cellular activity | 81 | pm/min/mg | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 91 | g | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 94 | % |
HEK293 cells
|
Normal
|
||
| Cellular activity | 94.6 | mg | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 95 | % |
HEK293 cells
|
Normal
|
||
| Cellular activity | 98 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 99.65 | % |
LNCaP cells
|
Prostate carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0 | nM |
CV-1 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 0.05 | nM |
C2C12 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.05 | nM |
SAOS-2 cells
|
Osteosarcoma
|
||
| Half Maximal Effective Concentration (EC50) | 0.1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 0.13 | nM |
C2C12 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 0.14 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 0.18 | nM |
HEK293 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 0.5 | nM |
MDA-kb2 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 0.5 | nM |
MDA-kb2 cells
|
Breast adenocarcinoma
|
||
| Cell-based Potency | 0.6 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.67 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 0.97 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
COS-7 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM |
MDA-MB-453 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 1.259 | nM |
NIH3T3 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.82 | nM |
HepG2 cells
|
Hepatoblastoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >10 | nM |
CV-1 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >>1000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
COS-7 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
COS-7 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
COS-7 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
COS-7 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
COS-7 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
CV-1 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
CV-1 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
CV-1 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
CV-1 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
CV-1 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM |
CV-1 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Potency | 10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >10000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 11 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Potency | 11220.2 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Potency | 11220.2 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 12 | nM |
COS-7 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1247 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Potency | 12589.3 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Potency | 12589.3 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 13.1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 1400 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 15 | nM |
COS-7 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 15 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Potency | 15848.9 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Potency | 15848.9 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Potency | 17782.8 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 18 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 18.5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Potency | 19952.6 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Potency | 19952.6 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >19952.62 | nM |
Vero C1008 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 2 | nM |
MDA-MB-453 cells
|
Breast adenocarcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2.1 | nM |
HEK293 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2.2 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2.239 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2.305 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2.6 | nM |
HEK293 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2.6 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 2.8 | nM |
C2C12 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 20 | nM |
COS-7 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | >20000 | nM |
Vero C1008 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 20000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2100 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2100 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 23 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Potency | 24336.5 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Potency | 25118.9 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Potency | 26603.2 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Potency | 28183.8 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Potency | 29092.9 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 3 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 3.1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 3.1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 3.8 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 3.981 | nM |
NIH3T3 cells
|
Normal
|
||
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Potency | 31622.8 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Potency | 31622.8 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 3200 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Potency | 32196.8 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 340000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 340000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Potency | 3548.1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Potency | 35481.3 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Potency | 35481.3 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 360 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 39.6 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 4 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 440 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 440 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Potency | 446.7 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 4490 | nM |
CHO cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 5 | nM |
CV-1 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 5.1 | nM |
CV-1 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 5.1 | nM |
CV-1 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 5.1 | nM |
CV-1 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 5.1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 5.1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 5.3 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 5.7 | nM |
CV-1 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 5.7 | nM |
CV-1 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 5.7 | nM |
CV-1 cells
|
Normal
|
||
| Half Maximal Activity Concentration (AC50) | 5.8 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Potency | 50118.7 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Potency | 50118.7 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 540 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 6 | nM |
CV-1 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 6 | nM |
CV-1 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 6 | nM |
CV-1 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 6 | nM |
CV-1 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 6.2 | nM |
COS-7 cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 6.2 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cell-based Potency | 66824.2 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Potency | 66824.2 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Potency | 7.1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 7300 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Potency | 7943.3 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Potency | 79432.8 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Cellular activity | 8 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Cellular activity | 8 | nM |
HeLa cells
|
Human papillomavirus-related endocervical adenocarcinoma
|
||
| Half Maximal Effective Concentration (EC50) | 8200 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Potency | 89125.1 | nM | Undisclosed | Undisclosed | Undisclosed |
Each Antibody-drug Conjugate Related to This Payload